Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study

Frontiers in Microbiology
Ying Wei TangJeanette W P Teo

Abstract

Mycobacterium abscessus complex consist of three rapidly growing subspecies: M. abscessus, M. massiliense, and M. bolletii. They are clinically important human pathogens responsible for opportunistic pulmonary and skin and soft tissue infections. Treatment of M. abscessus infections is difficult due to in vitro resistance to most antimicrobial agents. Tedizolid (TZD) is a next-generation oxazolidinone antimicrobial with a wide spectrum of activity even against multidrug resistant Gram-positive bacteria. In this study, the in vitro activity of TZD against the M. abscessus complex (n = 130) was investigated. Susceptibility testing by broth microdilution showed lower TZD minimum inhibitory concentrations (MICs) when compared to linezolid. The MIC50 and MIC90 was 1 mg/L and 4 mg/L, respectively across all M. abscessus complex members, reflecting no difference in subspecies response to TZD. Pre-exposure of M. abscessus complex to subinhibitory concentrations of TZD did not trigger any inducible drug resistance. Single-drug time kill assays and bactericidal activity assays demonstrated bacteriostatic activity of TZD in all three M. abscessus subspecies, even at high drug concentrations of 4 to 8x MIC. Combination testing of TZD with ...Continue Reading

References

Sep 14, 2010·American Journal of Respiratory and Critical Care Medicine·Won-Jung KohO Jung Kwon
Nov 16, 2010·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yi-Ching HuangZhi-Yuan Shi
Nov 26, 2010·Journal of Clinical Microbiology·Edouard MacherasBeate Heym
Feb 1, 2012·The Journal of Antimicrobial Chemotherapy·Rachid NessarBrigitte Gicquel
Aug 11, 2012·American Journal of Respiratory and Critical Care Medicine·Go-Eun ChoiWon-Jung Koh
Apr 2, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jamie J KisgenLindsey M Childs
Oct 1, 2014·Pharmacotherapy·Jeffrey M RybakCraig A Martin
Oct 1, 2014·Current Opinion in Infectious Diseases·Jeana L Benwill, Richard J Wallace
Oct 27, 2014·The Journal of Antimicrobial Chemotherapy·Beatriz E FerroJohan W Mouton
Feb 7, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S S TangL Y Hsu
Apr 8, 2015·Antimicrobial Agents and Chemotherapy·Rasmus N KlitgaardBirte Vester
Aug 12, 2015·Antimicrobial Agents and Chemotherapy·Amit KaushikGyanu Lamichhane
Aug 22, 2015·Emerging Infectious Diseases·Meng-Rui LeePo-Ren Hsueh
Jan 1, 2014·Antibiotics·Juan Carlos Palomino, Anandi Martin
Mar 24, 2017·Journal of Clinical Microbiology·Barbara A Brown-Elliott, Richard J Wallace
Apr 12, 2017·Antimicrobial Agents and Chemotherapy·Dinah Binte AzizThomas Dick
Aug 2, 2017·Antimicrobial Agents and Chemotherapy·Matthew B McNeilTanya Parish
Dec 9, 2017·Diagnostic Microbiology and Infectious Disease·Fabrice CompainVincent Dubée

❮ Previous
Next ❯

Citations

May 15, 2020·The Pediatric Infectious Disease Journal·Angela BerkhoutDavid Burgner
Jun 22, 2019·The European Respiratory Journal·Steven CowmanMichael R Loebinger
Sep 20, 2020·International Journal of Molecular Sciences·Michal Meir, Daniel Barkan
Dec 19, 2020·The Journal of Antimicrobial Chemotherapy·Ka Lip ChewJeanette Teo
Jun 25, 2021·Future Medicinal Chemistry·Christophe R CantelliPascal Sonnet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.